News
Augtyro

FDA widens label for BMS’ cancer drug Augtyro

Bristol-Myers Squibb has claimed FDA approval for a new, tumour-agnostic indication for Augtyro, the cancer drug it acquired as part of its $4.1 billion takeover of Turning Point Therapeuti

Oncology
Paul Burton interview with Jonah Comstock

ASCO 2024 - Paul Burton

For Amgen, ASCO 2024 was all about lung cancer, with encouraging data in both non-small cell and small cell lung cancer.

News

Views & Analysis

Deep Dive

Oncology
navigation illustration

Deep Dive: Oncology 2024

Join our exploration of vital oncology topics, including caring for cancer survivors, AI in patient care, the future of CAR-T therapies, and the rise of targeted radiopharmaceuticals.

Newsletters and Deep Dive
digital magazine

Webinars

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Oncology
Print
Sponsored

Clinical decision-making insights for haem/oncs

Despite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several decision-making challenges for healthcare professionals.

Podcasts

Video

Oncology
Dr Meredith McKean interview with Nicole Raleigh

ESMO 2024 – Dr Meredith McKean

In our final video from ESMO 2024, web editor Nicole Raleigh spoke with Dr Meredith McKean, a melanoma investigator at the Sarah Cannon Research Institute.

Oncology
ESMO 2024 Dr Magda Meissner interview with Nicole Raleigh

ESMO 2024 – Magda Meissner

In our penultimate video from ESMO 2024, pharmaphorum spoke with Dr Magda Meissner, consultant medical oncologist at the Velindre Cancer Centre and project lead for QuicDNA, about how a sim

Oncology
Nicole Raleigh interview with Daejin Abidoye at ESMO 2024

ESMO 2024 - Daejin Abidoye

At ESMO 2024, AbbVie presented new data across their solid tumour pipeline, displaying the company’s potential as an emerging leader in solid tumours.

White Papers

Debates & Insight

Partner Content

Oncology
9th Tumor Models San Francisco Summit 2025 banner
Partner Content

9th Tumor Models San Francisco Summit 2025

Implement State-of-the-Art, Reproducible & Predictive in vivo & in vitro Oncology Models to Successfully Identify Promising Targets & Biomarkers, & Surmount the Translationa